Redcare Pharmacy at a Crossroads: Reform Could Fuel Demand but Shipping Curbs Tighten the Screws

Redcare faces opposing regulatory forces: new law expands local pharmacy services, while draft shipping rules could choke its online model. Investors watch Bundesrat vote.

The political pendulum is swinging both ways for Redcare Pharmacy. Berlin has just passed a sweeping overhaul of the pharmacy sector that promises to bolster local dispensaries, yet a parallel regulatory push on shipping rules threatens to choke the very online model that has made Redcare the dominant digital player in Germany. The result is a stock caught between two opposing forces — and investors are watching the Bundesrat closely.

The reform that opens doors — and closes some

On 22 May 2026, the Bundestag approved the Apothekenversorgung-Weiterentwicklungsgesetz with the backing of the CDU/CSU and SPD coalitions. The AfD and Greens voted against the amended version, while Die Linke abstained. The next hurdle is the Bundesrat, which could take up the bill on 12 June, with implementation expected later this summer.

The legislation gives brick-and-mortar pharmacies a wider remit. They will be allowed to offer vaccinations (excluding live vaccines), rapid diagnostic tests, preventive services and blood draws for adults. In clearly defined cases — such as follow-up prescriptions for chronic conditions or minor acute complaints — pharmacists can dispense certain medicines without a new doctor’s script. The precise criteria are to be set by the Federal Institute for Drugs and Medical Devices (BfArM) in consultation with medical and pharmacy associations within a year.

The political motivation is stark: Germany’s pharmacy network is shrinking. At the end of 2025 there were only 16,601 pharmacies nationwide, a decline of 440 outlets year-on-year — a drop of 2.6%. The slide continued into the first quarter, when 81 closures versus just 19 new openings left the country with 16,533 stores by the end of March. That represents a roughly 20% contraction compared with 2013.

Versandverbot durch die Hintertür?

For Redcare, however, the expansion of local pharmacy duties is not the immediate threat. Far more consequential is a separate regulation being drafted under the Apothekenbetriebsordnung. It proposes stricter rules for the shipping and transport of numerous medicines, including comprehensive contractual and documentation requirements as well as continuous temperature monitoring — especially for products requiring a stable cold chain. Logistics providers would have to prove compliance with storage and transit conditions and alert the pharmacy if problems arise.

CEO Olaf Heinrich has labelled the proposals a “systemic break” and warned that they amount to a “shipping ban through the back door”. More than 26 million patients in Germany currently use mail-order pharmacy services, and Heinrich argues that cutting off that channel would undermine a vital supply route.

The timing is particularly delicate. Redcare has designated 2026 as a peak investment year. A new logistics centre in Pilsen, Czech Republic, is set to boost annual capacity by 15 million parcels. The company’s entire growth strategy depends on scalable, cost-efficient distribution — exactly what the new shipping rules could jeopardise.

Q1 growth, margins under pressure

Indeed, Redcare is still expanding rapidly. First?quarter revenue climbed to €849.5 million from €717.3 million a year earlier, while the net loss narrowed slightly to €10.5 million from €10.8 million. Management reaffirmed its full?year growth target of 13?15%. The company now controls 67% of the German online prescription market.

Yet that expansion comes at a price. The group has trimmed its medium?term EBITDA margin target from above 8% to more than 5%, and for 2026 it is aiming for an adjusted EBITDA margin of at least 2.5%. Growth, for now, clearly takes precedence over profitability.

Analysts see value, but the stock is bruised

The market has already priced in the uncertainty. Redcare shares closed at €43.12 on Thursday, down 2.93% on the day, bringing the year?to?date loss to 35.83%. The stock is essentially flat against its 50?day moving average of €43.11, but remains 29.40% below its 200?day line of €61.08.

Despite the battered chart, several analysts remain constructive. The consensus price target stands at roughly €90, with Deutsche Bank nailing a particularly bullish target of €99. The reform, they argue, could trigger a re?rating — but only if the final shipping regulation does not cripple the online model.

What’s next

The immediate catalyst is the Bundesrat vote on 12 June. After that, the detail of the shipping ordinance will determine whether Redcare can fully exploit its logistics investments or faces a cost hike that squeezes margins. The half?year report on 29 July will provide the next hard data on how the company is navigating this political crosswind. For now, the shares are caught in the gap between structural demand for digital pharmacy and a regulatory environment that may yet slam the brakes on the sector’s biggest player.